Wavetrue Inc 2018 Q3 Institutional Investor Sentiment Worse Than Expected

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Logo

Sentiment for Wavetrue Inc (NASDAQ:PRTK)

Wavetrue Inc (NASDAQ:PRTK) institutional sentiment decreased to 1.16 in 2018 Q3. Its down -0.18, from 1.34 in 2018Q2. The ratio dropped, as 43 hedge funds opened new or increased stock positions, while 37 sold and decreased equity positions in Wavetrue Inc. The hedge funds in our partner’s database now have: 20.75 million shares, down from 20.80 million shares in 2018Q2. Also, the number of hedge funds holding Wavetrue Inc in their top 10 stock positions decreased from 2 to 1 for a decrease of 1. Sold All: 13 Reduced: 24 Increased: 30 New Position: 13.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. The company has market cap of $203.88 million. The Company’s lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections , community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. It currently has negative earnings. The firm has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP.

The stock increased 1.20% or $0.08 during the last trading session, reaching $6.32. About 80,917 shares traded. Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has declined 61.02% since January 14, 2018 and is downtrending. It has underperformed by 61.02% the S&P500.

Analysts await Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) to report earnings on March, 7. They expect $-0.61 earnings per share, up 21.79 % or $0.17 from last year’s $-0.78 per share. After $-1.01 actual earnings per share reported by Paratek Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -39.60 % EPS growth.

Abingworth Llp holds 5.97% of its portfolio in Paratek Pharmaceuticals, Inc. for 1.04 million shares. Roumell Asset Management Llc owns 251,766 shares or 4.48% of their US portfolio. Moreover, Highland Capital Management Lp has 1.42% invested in the company for 2.65 million shares. The New York-based Trellus Management Company Llc has invested 1.4% in the stock. Arbiter Partners Capital Management Llc, a New York-based fund reported 992,146 shares.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ratings Coverage

Ratings analysis reveals 50% of Paratek Pharmaceuticals’s analysts are positive. Out of 2 Wall Street analysts rating Paratek Pharmaceuticals, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $13 while the high is $14. The stock’s average target of $13.50 is 113.61% above today’s ($6.32) share price. PRTK was included in 2 notes of analysts from August 27, 2018.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ratings Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.